National Institute of Allergy and Infectious Diseases
  National Institutes of Health
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Biodefense and Related Programs
 Biodefense
  About
  For Researchers
   Introduction
   Resources
   Funding
    FY2003 Awards
    FY2004 Awards
    FY2005 Awards
    FY2006 Awards
    FY2007 Awards
   Meetings
   Category A-C Pathogens
  Public and Media
 Radiation Countermeasures
 Chemical Countermeasures


Biodefense

Expired Research Opportunities

Target Identification

Programs to identify potential vaccines, diagnostics, and immunotherapy targets. This page includes EXPIRED funding opportunities only.

Cooperative Research Partnerships for Biodefense and Emerging Infectious Diseases (RFA-AI-08-001)

Focus: To support the development of new vaccines, vaccine technologies, adjuvants, therapeutics, immunotherapeutics or medical diagnostics focused on NIAID Category A, B, or C priority pathogens and toxins
Contact Info
Dr. Michael Schaefer
E-mail: mschaefer@niaid.nih.gov

Cooperative Research Partnerships into Therapeutics and Diagnostics for Biodefense Toxins (U01) (RFA-AI-06-035)

Focus: To support cooperative translational research into developing therapeutics and diagnostics for certain biodefense toxins: Shiga toxins, ricin toxin, the Staphylococcus enterotoxin B (SEB), Clostridium perfringens epsilon toxin, and the botulinum neurotoxins.
Contact Info
General scientific, technical, and programmatic issues: Clare K. Schmitt
E-mail: CSchmitt@niaid.nih.gov
Therapeutics and immunotherapeutics questions: Lillian Van De Verg
E-mail: LVanDeVerg@niaid.nih.gov
Diagnostics questions: Robert H. Hall
E-mail: rhall@niaid.nih.gov

Cooperative Research into Therapeutics and Diagnostics for Category B Bacteria, Viruses, and Parasites (U01) (RFA-AI-06-029)

Focus: To support translational research and pre-clinical product development of new therapeutics and diagnostics addressing NIAID Category B priority pathogens.
Contact Info
General scientific and programmatic issues and questions, Category B Bacteria: Robert Hall
E-mail: rhall@niaid.nih.gov
Questions related to Category B viruses: Cristina Cassetti
E-mail: ccassetti@niaid.nih.gov
Questions related to Category B parasites: Philip Coyne
E-mail: pcoyne@niaid.nih.gov

Cooperative Research Partnerships for Influenza Product Development (U01) (RFA-AI-06-02)

Focus: To support research that will advance the development of vaccines, adjuvants, therapeutics, immunotherapeutics, and diagnostics for influenza technologies through the product development pathway.
Contact Info
E-mail:
General scientific, technical, and programmatic issues; vaccines, therapeutics, and immunotherapeutics: David Cho
E-mail: choda@niaid.nih.gov
Cooperative research partnerships: Michael Schaefer
E-mail: mschaefer@niaid.nih.gov
Adjuvants: Sonnie Kim
E-mail: skim@niaid.nih.gov
Diagnostics: Karen Lacourciere
E-mail: lacourcierek@niaid.nih.gov

back to top

E-mail Icon E-mail this page
Print Icon Print this page